相关报告：智研咨询发布的《2019-2025年中国疫苗行业市场调查及发展趋势研究报告》
2018年12月口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（POLIOMYELITIS (LIVE) VACCINE TYPE Ⅰ TYPE Ⅲ (HUMAN DIPLOID CELL),ORAL）批签发产品共457935瓶，其中北京北生研生物制品有限公司批签发457935瓶。
2018年12月口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（POLIOMYELITIS (LIVE) VACCINE TYPE Ⅰ TYPE Ⅲ (HUMAN DIPLOID CELL),ORAL）生物制品批签发产品情况
产品名称 | 规格 | 批号 | 签发量 | 生产企业 | 签发结论 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806110 | 41895瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201807112 | 41955瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201807111 | 41565瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806102 | 40305瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806109 | 41895瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806108 | 41955瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806107 | 41445瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806106 | 41415瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806105 | 41865瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806104 | 42315瓶 | 北京北生研生物制品有限公司 | 予以签发 |
口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）（Poliomyelitis (Live) Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral） | 每瓶2.0ml(20人份)。每1次人用剂量为2滴(相当于0.1ml),含脊髓灰质炎活病毒总量应不低于6.21 lgCCID50,其中Ⅰ型应不低于6.0 lgCCID50,Ⅲ型应不低于5.8 lgCCID50。(Total amount of poliovirus per dose(2 drops:0.1ml) should be not less than 6.21 lgCCID50. The value of virus titer is not less than 6.0 lgCCID50 for type Ⅰ and not less than 5.8 lgCCID50 for type Ⅲ ) | 201806103 | 41325瓶 | 北京北生研生物制品有限公司 | 予以签发 |
数据来源：中国食品药品检定研究院，智研咨询整理
版权提示：智研咨询倡导尊重与保护知识产权，对有明确来源的内容注明出处。如发现本站文章存在版权、稿酬或其它问题，烦请联系我们，我们将及时与您沟通处理。联系方式：gaojian@chyxx.com、010-60343812。
